Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 10  •  04:00PM ET
11.42
Dollar change
+0.41
Percentage change
3.72
%
Index
RUT
P/E
-
EPS (ttm)
-0.93
Insider Own
5.03%
Shs Outstand
34.25M
Perf Week
4.58%
Market Cap
392.28M
Forward P/E
-
EPS next Y
-1.11
Insider Trans
-
Shs Float
32.63M
Perf Month
-7.00%
Enterprise Value
204.37M
PEG
-
EPS next Q
-0.28
Inst Own
93.71%
Perf Quarter
-6.24%
Income
-38.96M
P/S
-
EPS this Y
-7.62%
Inst Trans
16.58%
Perf Half Y
-19.01%
Sales
0.00M
P/B
2.09
EPS next Y
1.77%
ROA
-28.89%
Perf YTD
-15.22%
Book/sh
5.47
P/C
2.08
EPS next 5Y
5.01%
ROE
-29.59%
52W High
17.15 -33.41%
Perf Year
-4.36%
Cash/sh
5.50
P/FCF
-
EPS past 3/5Y
69.76% 62.31%
ROIC
-20.74%
52W Low
9.85 15.94%
Perf 3Y
206.04%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
5.44% 5.64%
Perf 5Y
-86.48%
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
68.74%
Oper. Margin
-
ATR (14)
0.65
Perf 10Y
-97.33%
Dividend Ex-Date
-
Quick Ratio
67.69
Sales Y/Y TTM
-100.00%
Profit Margin
-
RSI (14)
54.41
Dividend Gr. 3/5Y
- -
Current Ratio
67.69
EPS Q/Q
22.74%
SMA20
3.13%
Beta
0.20
Payout
-
Debt/Eq
0.01
Sales Q/Q
-
SMA50
1.05%
Rel Volume
0.92
Prev Close
11.01
Employees
19
LT Debt/Eq
0.00
SMA200
-9.86%
Avg Volume
157.33K
Price
11.42
IPO
Jun 23, 2014
Option/Short
Yes / Yes
Trades
Volume
144,569
Change
3.72%
Date Action Analyst Rating Change Price Target Change
Jul-07-25Initiated TD Cowen Buy
Dec-16-24Initiated H.C. Wainwright Buy $28
Dec-13-24Initiated Robert W. Baird Outperform $30
Oct-16-24Initiated Oppenheimer Outperform $35
Sep-12-24Initiated Guggenheim Buy $17
Jul-22-24Initiated Leerink Partners Outperform $13
Jun-13-24Initiated Piper Sandler Overweight $30
Oct-05-20Downgrade Ladenburg Thalmann Buy → Neutral
Apr-20-20Initiated Ladenburg Thalmann Buy $14
Feb-26-16Downgrade Maxim Group Buy → Hold
Mar-10-26 07:00AM
Mar-09-26 07:00AM
Feb-23-26 07:00AM
Feb-12-26 08:30AM
Jan-11-26 08:00AM
09:55AM Loading…
Dec-24-25 09:55AM
Dec-05-25 09:55AM
Dec-03-25 09:35AM
Nov-18-25 06:16AM
Nov-14-25 05:00PM
Nov-12-25 09:45AM
Nov-06-25 12:19AM
Nov-05-25 04:43PM
Nov-03-25 07:10AM
07:00AM
07:00PM Loading…
Nov-02-25 07:00PM
Sep-22-25 04:05PM
Jul-09-25 08:00AM
Jun-20-25 09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
09:40AM
Jun-16-25 08:50AM
Jun-05-25 09:55AM
Jun-04-25 09:40AM
08:50AM Loading…
May-29-25 08:50AM
May-20-25 09:55AM
May-19-25 09:40AM
May-14-25 07:00AM
May-05-25 08:50AM
May-02-25 09:40AM
Apr-30-25 10:17AM
Apr-25-25 09:55AM
Apr-23-25 12:00PM
Apr-16-25 09:40AM
Apr-15-25 11:51PM
Mar-28-25 09:00AM
Mar-25-25 08:00AM
Mar-19-25 07:00AM
Feb-26-25 07:00AM
Feb-20-25 09:55AM
Feb-14-25 08:10AM
08:00AM
Jan-27-25 08:00AM
Jan-13-25 09:49AM
Dec-17-24 06:25AM
Dec-09-24 09:55AM
08:50AM
Nov-26-24 07:00AM
Nov-14-24 04:30PM
Nov-04-24 08:00AM
Oct-25-24 05:01PM
Oct-14-24 06:00AM
Oct-12-24 06:30AM
Sep-30-24 09:03PM
Sep-26-24 04:30PM
Sep-18-24 08:00AM
Sep-17-24 08:00AM
Jul-15-24 06:00AM
Jul-01-24 07:00AM
May-13-24 02:53PM
08:15AM
May-01-24 08:00AM
Apr-18-24 07:30AM
07:00AM
Apr-09-24 08:00AM
Mar-24-24 07:55AM
Feb-13-24 08:00AM
Nov-30-23 07:00AM
Nov-17-23 08:00AM
Nov-13-23 08:00AM
Sep-21-23 08:00AM
Aug-21-23 09:02PM
Aug-18-23 09:02PM
Aug-11-23 01:00PM
Aug-08-23 10:30PM
Jul-25-23 01:00PM
Jun-26-23 08:00AM
May-15-23 08:00AM
May-08-23 08:05AM
08:00AM
Feb-13-23 08:00AM
Jan-23-23 09:48AM
Nov-10-22 08:00AM
Sep-16-22 08:42AM
Sep-12-22 10:06PM
Sep-02-22 08:00AM
Jul-15-22 06:52AM
May-16-22 08:15AM
Feb-14-22 08:00AM
Jan-18-22 12:53PM
Jan-17-22 09:30AM
Nov-27-21 06:54AM
Nov-15-21 08:00AM
Sep-20-21 08:00AM
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 29 '25Buy13.4477,3871,040,0819,700,195Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 23 '25Buy12.8550,000642,5009,620,075Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 26 '25Buy13.1016,836220,5529,634,395Dec 29 07:31 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 22 '25Buy12.0819,542236,0679,577,475Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 19 '25Buy11.4816,384188,0889,560,825Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorDec 18 '25Buy11.2410,215114,8179,546,875Dec 22 07:45 PM
SUVRETTA CAPITAL MANAGEMENT, LDirectorNov 07 '25Buy13.501,481,48119,999,9949,538,175Nov 10 09:51 PM